cyrilzakka/clinical-trials huggingface dataset:
Race and Socioeconomic Position: Examining Common Social Pathways to Disease Risk

Black Americans and those of lower socioeconomic position (SEP) are at higher risk for multiple diseases of aging and shorter lifespans, but the psychophysiological mechanisms that may account for these effects are not clear. The overarching objective of this pilot grant is to improve our understanding of the proximal social exposures and subsequent psychobiological processes that contribute to racial and socioeconomic health disparities. Precisely understanding what these mutable social and psychological mechanisms are is necessary in order to identify intervention targets at the level of the individual.

Black Americans and those of lower socioeconomic position (SEP) are at higher risk for multiple diseases of aging and shorter lifespans. Though these disparities are well-documented, the mechanisms that may account for them are still poorly understood. Low income or Black race do not, themselves, cause individuals to become sick. Instead, the social context and exposures associated with these personal attributes give rise to differential risk (1-3). Black race and lower SEP are overlapping in the United States and race and SEP may share common social exposures that contribute to disease risk because both Blacks and individuals of lower SEP are socially marginalized (e.g., devalued, pushed to the lower margins of society) and thus exposed to more stress associated with lower hierarchical rank (4). However, no studies to our knowledge have been designed to examine whether day-to-day social exposures common across race and SEP may contribute to higher overall disease burden in these groups. In this project, investigators examine whether daily social interaction patterns help to explain how race and SEP may be linked with well-established psychobiological pathways to disease (affect, behavior, and physiology). With respect to each of these pathways, investigators examine the extent to which within-person changes in social processes may be associated with effects that mirror (and thus could explain) between-group differences. For example, interactions in which one experiences a higher degree of disrespect may be associated with momentary changes in affect, behavior, and physiology that confer disease risk. Examination of these within-person processes allows for stronger causal inference and is directly relevant to the development of individual-level interventions (e.g., targeting cognitive, behavioral, and affective processes). These findings can directly inform individual and group interventions for stress reduction in health disparity populations.

Eligibility Criteria:
Inclusion Criteria:

- Black American or White American between the ages of 35 and 70.

Exclusion Criteria:

* Conditions that require immediate treatment (e.g., Stage 2 hypertension; resting blood pressure \> 160/100 mmHg)
* Excessive alcohol consumption (\> 5 portions, \> 3 times per week)
* Frequent illicit drug use
* Schizophrenia or bipolar disorder
* Permanent neurological deficit
* Shift work
* Current pregnancy
Ultralow Dose PET Imaging for PSMA Expression

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is:

Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard?

Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours

This research study aims to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. "Investigational" means that the procedure or drug being studied is not yet approved by the FDA for the specific use being tested in this research. The PET imaging technique used in this study is considered investigational because it is being tested at an ultralow radiation dose that has not yet been approved for clinical use. The radiotracer, 18F-DCFPyL, is FDA-approved for detecting prostate cancer at standard doses.

18F-DCFPyL attaches to a protein called PSMA, which is often found at higher levels on certain cancer cells, such as prostate cancer cells. In this study, investigators will use a very small amount of this tracer (less than 1/20th of the standard dose) along with advanced PET imaging technology to see if it is possible to create clear images while using much less radiation. This study aims to develop a safer imaging technique that could potentially be used more frequently for screening and monitoring prostate cancer.

Investigators will enroll individuals with and without prostate cancer to evaluate how ultralow dose PET imaging detects PSMA in different type of tissue.

Approximately 200 people will be enrolled in this study at the Nuclear Imaging Institute.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18 years.
2. Ability to provide informed consent and comply with study procedures.
3. For female participants:

   * Must not be pregnant or breastfeeding.
   * Negative pregnancy test required for women of childbearing potential.

Exclusion Criteria:

1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).
2. More than four prior enrollments in this study.
3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
4. Medication \& Prior Treatment Exclusions

   • Concurrent PSMA-targeted therapy (e.g., lutetium-177).
5. Pregnant or breastfeeding individuals (negative pregnancy test required)
6. Inability to provide informed consent
7. Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.
Effect of Reminiscence Therapy on Older Adults

This study was conducted to examine the effect of reminiscence therapy on the functionality of older adults aged 65 and over living in nursing homes.

ABSTRACT Objective : This study was conducted to examine the effect of reminiscence therapy on the level of functionality of individuals aged 65 and over.

Method: The sample of the study consisted of 16 residents who lived in a public nursing home between December 2019 and February 2020 and agreed to participate in the study. Participants were divided into intervention and control groups using the simple random sampling method. Reminiscence therapy was performed with each participant in the intervention group for 8 weeks. The participants in the control group received routine services and were regularly visited for 8 weeks. The research data were obtained by implementing the "Personal Information Form," "Multidimensional Observation Scale for Elderly Subjects (MOSES), and "Mini Mental State Examination (MMSE)" with all participants before the reminiscence therapy and at the end of week eight. Non-parametric tests were completed in analyzing the data as the sample size was lower than 30.

Findings: It was determined that 87.5% of the participants in the intervention group had a chronic disease, 50% were male, and 37.5% were elementary school graduates. All the participants in the control group had a chronic disease, 62.5% were male, and 50% were elementary school graduates. When the pre- and post-reminiscence therapy results were compared, a significant difference was found in the MMSE and MOSES (in the areas of disoriented behavior, depressed/anxious mood, and withdrawn behavior) scores in the intervention group. In the post-test evaluation, a significant difference was found between the intervention and comparison group in MOSES scores. It was determined that the participants in the intervention group that received reminiscence therapy had better functional and cognitive competency than the control group in the areas of self-care, depression/anxiety, and withdrawal from society.

Conclusion: It was concluded that the reminiscence therapy contributed to increase the mental competence and functionality of the older adult participants.

Eligibility Criteria:
Inclusion Criteria:

* were 65 years of age and older
* had a Standardized Mini Mental Test (SMMT) score between 24 and 30
* Individuals who did not have communication difficulties and mental problems
* agreed to participate in the study were included in the study sample.

Exclusion Criteria:

* were 64 years of age and younger
* have communication difficulties and mental problems
* had a Standardized Mini Mental Test (SMMT) score 24 and more less
* nor agreed to participate in the study.
Harvest, Isolation and Culture of Cardiac Stem Cells From Endomyocardial Biopsies

The purpose of this study is to determine whether the harvest, isolation and culture of cardiac stem cells from endomyocardial biopsies is feasible.

Heart failure is a devastating condition affecting nearly 6 million patients in the United States alone. Ischemic cardiomyopathy, or pump failure secondary to previous heart attack, is considered by many to be the leading cause of heart failure. Stem cell therapy, or regeneration of the lost myocardium, is an intervention that has the potential for reversing the detrimental effects of this disease. Recently published evidence has shown preliminary results indicating the safety and feasibility of utilizing cardiac stem cells for the treatment of ischemic cardiomyopathy. The ability to use a commonly practiced method, such as endomyocardial biopsy, to isolate and expand stem cell cultures could, potentially, make this therapy widely available. The results of this study will be important for the design of future clinical trials.

Eligibility Criteria:
Inclusion Criteria:

1. Any heart failure patient scheduled for RHC without contraindication for biopsy.
2. Any patient undergoing biopsy for diagnostic purposes may also be included in the study.

Exclusion Criteria:

1. Severe comorbidities (AST, ALT, serum creatinine \> 3 times the upper limit of normal).
2. Pregnancy or women of childbearing potential.
3. Anticoagulation which cannot be stopped for 5-7 days.
4. Hepatitis B, C or HIV.
5. Inability to give informed consent.
Absorption and Digestion Kinetics of Human Metabolites

The purpose of this pilot study is to evaluate the effects oral supplementation with four human metabolites (spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide(OEA)) at varying doses on the circulating blood levels of these metabolites as well as their immediate effects on plasma functionality and postprandial inflammation. 5 young healthy subjects will participate in a four armed study consisting of a Placebo arm and a Low, Medium, and High Dose arm. Subjects will be given a standardized breakfast along with supplementation with either an escalating dose (Low: 1x, Medium: 2x, High: 3x) of a combination of spermidine, nicotinamide, PEA and OEA or a placebo control and a time course of their blood plasma will be collected after supplementation. Plasma samples will be assessed for their concentration of spermidine, nicotinamide, PEA, and OEA as well as their experimental and clinical functionalities including their anti-inflammatory, antioxidant, and cholesterol efflux abilities on primary human macrophage.


Eligibility Criteria:
Inclusion Criteria:

* Age: 20-40 years old to constitute a young study population
* BMI: 19-27 kg/m2 to constitute a normal/healthy weight population
* Weight: 133lbs or more
* Subjects must be willing and able to consume a standardized breakfast bar containing cashews and dates (Larabar).
* Subjects must be willing to consume oral dietary supplement versions of spermidine, 1-methlynicotinamide, palmitoylethanolamide, and oleoylethanolamide.
* Subjects must be willing and able to undergo blood draws at the UC Davis Ragle Nutrition Center at 0, 1, 2, and 4 hours after supplementation with spermidine, niacinamide, palmitoylethanolamide, and oleoylethanolamide.

Exclusion Criteria:

* Smoker
* Anemia
* Documented chronic diseases including diabetes, thyroid disease, metabolic syndrome, cancer, autoimmune diseases, or previous cardiovascular events
* Any inflammatory bowel disease including IBS, Crohn's Disease, Celiac Disease
* Any allergy or sensitivity to wheat, gluten, or soy products
* Consumption of \>1 alcoholic drink/day
* Current consumption of any probiotic, prebiotic, or dietary supplements
* Extreme dietary or exercise patterns
* Recent weight fluctuations (greater than 10% in the last six months)
* Regular use of over-the-counter allergy or pain medications (\>1/week)
* Taking prescription lipid medications (e.g. statins) or other supplements known to alter lipoprotein metabolism such as isoflavones.
* Use of any form of hormonal birth control including oral contraception pills, hormonal IUDs or rings, or hormonal birth control patches
* Illness such as flu or cold of any kind within the last two weeks
* Allergy to components of standardized breakfast bar (cashew/dates)
* Changes to any of the above during the study period.
Neck Liposuction for the Treatment of Obstructive Sleep Apnea

Liposuction, one of the most common cosmetic procedures performed in the United States, is a surgical technique used to reduce localized areas of excess subcutaneous fat. The neck is a common area of treatment, where liposuction reduces fat volume and neck size. We hypothesize that suctioned removal of fat of the neck will reduce the severity of obstructive sleep apnea.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-60 years of age
* Subjects must have documented mild to moderate obstructive sleep apnea(OSA) syndrome within the last year from the Northwestern University Sleep Clinic
* Subjects must qualify as "very sleepy" on the Epworth Sleepiness Scale
* Females must have neck circumference of 16.0 cm or greater, and males must have neck circumference of 17.0 cm or greater
* Subjects must be a good candidates for neck liposuction as determined by the study physician
* Subjects must be in good health and is able to undergo the liposuction procedure

Exclusion Criteria:

* Pregnant or lactating female
* Subjects who are unable to understand the protocol or to give informed consent
* Subjects dependent on blood thinners
* Subjects with bleeding diathesis
* Subjects with a history of poor wound healing, skin fragility, poor skin elasticity, or hypertrophic or keloidal scarring
* Subjects with a history of excessive surgeries on the neck in the area to be treated
* Subjects who are allergic to lidocaine or who have previously had an adverse reaction to epinephrine
* Subjects with non-apnea sleep disorders such as restless leg syndrome, insomnia, circadian rhythm disorders
* Subjects with chronic obstructive pulmonary disease
* Subjects with craniofacial abnormalities
* Subjects with hypoventilation
* Subjects with large tonsils/adenoids or an abnormal airway exam as determined by the study physician
* Subjects with an anatomical nasal obstruction
* Subjects who have a large tongue
* Subjects with severe cardiopulmonary risks as determined by the study physician
* Subjects who cannot complete an MRI
* Subjects who intend to pursue other treatments for OSA during the duration of this study
* Any previous and/or pending procedures at the treatment area or that may likely affect the treatment area
* Pending and/or anticipated major change in diet or exercise pattern in the six weeks following the last treatment
* Subjects with a Body Mass Index \>35kg/m2
* Subjects treated with continuous positive airway pressure (CPAP) within one month of study enrollment
Evaluation of a Low Fluoride Dentifrice for Caries Control

The aim of this randomized clinical trial is to evaluate the effect of pH and fluoride concentration in liquid dentifrices in the control of dental caries in early childhood, in non-fluoridated area. This study also aims to assess the effect of the consistency of liquid dentifrices in the fluoride uptake in the plaque and the fluoride concentration in the toenails, to estimate the fluoride intake from these formulations.

The study was carried out with schoolchildren living in a non-fluoridated area, with (A) or without (I) active caries lesions, were randomly allocated into 3 groups according to the LD used over 12 months: Group 1 (n=39-A/38-I): 550µgF/g-pH4.5, Group 2 (n=33-A/35-I) 1100µgF/g-pH7.0, Group 3 (n=33-A/34-I): 550µgF/g-pH7.0.

Eligibility Criteria:
Inclusion Criteria:

* Age 2 to 4 years;
* Not having participated in any other clinical study within 3 months prior to selection;
* Not having very large carious lesions or dentin sensitivity during the study;
* Signature of informed consent by the parents.

Exclusion Criteria:

* Using orthodontic appliances
Of 18F MEL050 Using PET/CT in Metastatic Melanoma

The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F MEL050 for finding sites of melanoma.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent obtained prior to any protocol-specific procedures
* Male and female patients with histologically confirmed melanoma
* At least one site of metastatic disease, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care
* Age \>/= 18 years
* Life expectancy \>/=3 months
* ECOG performance score of 0-2

Exclusion Criteria:

* Pregnant or breastfeeding females
* Systemic anti-melanoma therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F MEL050 PET/CT scan
* Patients whose clinical care may be compromised because of the delay resulting from performance of the 18F MEL050 PET/CT scan
* Patients whose only metastatic lesion is in the Central Nervous System
* Patients with urinary incontinence or patients who cannot comfortably hold their urine for more than 90 minutes
* Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study
* Patients unwilling or unable to comply with protocol and patients with a history of non compliance or inability to grant informed consent.
A Novel Analgesia Technique for ACL Reconstruction

A comparison of two anesthetic techniques-- the Adductor Canal Block (ACB) and the Adductor Canal Block with Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (ACB/IPACK)-- in patients undergoing bone-tendon-bone (BTB) anterior cruciate ligament (ACL) reconstruction.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing BTB ACL reconstruction with participating surgeon
* Age 13 or greater
* Planned use of regional anesthesia
* Ability to follow study protocol
* English speaking (secondary outcomes include questionnaires validated in English only)

Exclusion Criteria:

* Hepatic or renal insufficiency
* Younger than 13 years old
* Patients undergoing general anesthesia
* Allergy or intolerance to one of the study medications
* BMI \> 40
* Diabetes
* American Society of Anesthesiology (ASA) score IV
* Chronic gabapentin/pregabalin use (regular use for longer than 3 months)
* Chronic opioid use (taking opioids for longer than 3 months, or daily morphine equivalent of \>5mg/day for one month)
* Non-English speaking
Osteopathic Health Outcomes in Chronic Low Back Pain (OSTEOPATHIC) Trial

The purpose of this study is to determine whether osteopathic manipulative treatment (a type of spinal manipulative therapy used by osteopathic physicians) and ultrasound physical therapy are effective in the treatment of chronic low back pain.

The purpose of this study is to determine whether osteopathic manipulative treatment (a type of spinal manipulative therapy used by osteopathic physicians) and ultrasound physical therapy are effective in the treatment of chronic low back pain. This study uses a 2X2 factorial design to test the hypotheses.

Eligibility Criteria:
Inclusion Criteria:

* Must give a positive response to the question: "Have you had low back pain constantly or on most days for the last three months?"
* Must identify the low back as the primary site of pain
* Must agree to not receive any of the following outside of the study during the period of participation: osteopathic manipulative treatment, chiropractic adjustment (including "mobilization" or "manipulation"), physical therapy
* Women must not be pregnant or plan to become pregnant during the period of study participation (a negative pregnancy test and willingness to maintain an acceptable method of contraception will be required)

Exclusion Criteria:

* History of any of the following conditions which may be underlying causes of low back symptoms: cancer, spinal osteomyelitis, spinal fracture, herniated disc, ankylosing spondylitis, cauda equina syndrome
* History of surgery involving the low back within the past year or planned low back surgery in the future
* History of receiving Workers' Compensation benefits within the past three months
* Involvement in current litigation relating to back problems
* Current pregnancy or plan to become pregnant during the course of participation in the study
* Any of the following that may limit a provider's choice of osteopathic manipulative treatment techniques or hamper compliance with the study protocol: angina or congestive heart failure symptoms that occur at rest or with minimal activity, history of a stroke or transient ischemic attack within the past year
* Any of the following that may represent potential contraindications to receiving ultrasound physical therapy: implantation of a cardiac pacemaker, implantation of artificial joints or other biomedical devices, active bleeding or infection in the low back, pregnancy
* Use of intravenous, intramuscular, or oral corticosteroids within the past month
* History of osteopathic manipulative treatment, chiropractic adjustment, or physical therapy within the past three months or on more than three occasions during the past year
* Practitioner or student of any of the following: osteopathic medicine (D.O.) allopathic medicine (M.D.), chiropractic (D.C.), physical therapy
Intra-articular Injection of Allogeneic Platelet Rich Plasma (PRP) for Adhesive Capsulitis

The purpose of this study is to compare the efficacy of intra-articular allogenic Platelet Rich Plasma injection and steroid injection in the treatment of adhesive capsulitis of the shoulder.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female 18 years of age and older
2. Patients who have had pain at least for 12 months
3. limitation of both active and passive movements of the glenohumeral joint of ≥25% in at list 2 directions (abduction,flexion,external rotation,internal rotation), as compared with the contralateral shoulder in the scapular plane and in progressive degree of horizontal adduction

Exclusion Criteria:

1. Patients with concurrent bilateral shoulder pain
2. Patients with Diabetes mellitus
3. Patient with overt hypothyroidism or hyperthyroidism
4. Patients who received any drug by intra-articular injection for treatment within 6 months prior to this enrollment.
5. Patients who have a history of shoulder trauma including dislocation- subluxation- and fracture- breast cancer- or surgery around shoulder- neck and upper back
6. Patients with neurological deficit
7. Patients who have a History of allergic adverse reactions to corticosteroid
8. Patients with secondary adhesive capsulitis
9. Patients with systemic inflammatory disease including rheumatoid arthritis
10. Patients with degenerative arthritis, infectious arthritis of shoulder joint
11. Patients who have a history of shoulder trauma including dislocation, fracture
12. Patients taking anticoagulants
13. Patients who have a full-thickness rotator cuff tear
14. Patients who are difficulty participating in data collection due to communication problem and serious mental illness
15. Pregnant women or lactating mothers
16. Patients with cerebrovascular accident
17. Patients with symptomatic cervical spine disorders
18. Patients with serious condition which can affect this study such as severe cardiovascular diseases- renal diseases- liver diseases- endocrine diseases- and cancers